Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Male Sexual Response: Erection & Ejaculation01:17

Male Sexual Response: Erection & Ejaculation

Sexual stimulation can take various forms, such as physical touch and visual or auditory cues. When this happens, the parasympathetic reflex in the sacral portion of the spinal cord is activated. This reflex stimulates the release of nitric oxide (NO), which then dilates the arterioles in the penis, increasing blood flow to the erectile tissues - the corpora cavernosa and corpus spongiosum.
The blood filling the erectile tissues compresses the veins, which helps to prevent blood from leaving...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Sex Linked Disorders01:43

Sex Linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Which non pharmacological interventions should be offered to patients treated with androgen deprivation therapy for prostate cancer? A systematic review].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same author

Comparison of water vapor thermal therapy and prostate artery embolization for fragile patients with indwelling urinary catheters: Preliminary results from a multi-institutional study.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

Wnt/β-catenin pathway and cell adhesion deregulation in CSDE1-related intellectual disability and autism spectrum disorders.

Molecular psychiatry·2021
Same author

Treatment of benign prostate hyperplasia using the Rezum® water vapor therapy system: Results at one year.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[Short-term evaluation of Altis® single-incision sling in women stress urinary incontinence].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2020
Same author

[Retrospective multicentric evaluation of the efficacy of four-arms and adjustable male slings in the management of mild and moderate urinary incontinence after radical prostatectomy].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2019
Same journal

["Connected device for monitoring patients treated by prostatectomy: Implementation and qualitative assessment"].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Role of nurses specializing in oncology to support the care journey for patients with penile cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Pre- and post-prostatectomy rehabilitation by the certified nurse-urologist pair (REHAB): Feasibility study].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

[Genitourinary complications after pelvic radiotherapy: Diagnosis and management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2024
Same journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[Male contraception].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
See all related articles

Related Experiment Video

Updated: May 10, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

[Erectile dysfunction].

F Giuliano1, S Droupy

  • 1Neuro-uro-andrologie, service de médecine physique et réadaptation, université de Versailles Saint-Quentin en Yvelines, hôpital Raymond-Poincaré, Garches, AP-HP, 104, boulevard R.-Poincaré, 92380 Garches, France. francois.giuliano@uvsq.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|July 9, 2013
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) affects men of all ages, with prevalence increasing after 60. Standardized work-up and treatments, including PDE5 inhibitors, offer high success rates for most patients.

Keywords:
Dysfonction érectileEffets secondaires sexuelsEpidemiologyGuidelinesInhibiteurs de phosphodiestérase de type 5InhibitorsManagementPDE5Pharmacological treatmentPhysiopathologiePhysiopathologyPrise en chargeRecommandationsSexual side-effectsTraitement médicalÉpidémiologie

Related Experiment Videos

Last Updated: May 10, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Andrology
  • Sexual Medicine

Context:

  • Erectile dysfunction (ED) is a prevalent sexual disorder characterized by the inability to achieve or maintain an erection sufficient for sexual activity.
  • Risk factors include age, cardiovascular diseases, diabetes, and psychological disorders.
  • Pathophysiological mechanisms are diverse, involving neural, vascular, endothelial, and hormonal factors.

Purpose:

  • To review the prevalence, risk factors, pathophysiology, and treatment of erectile dysfunction.
  • To outline standardized diagnostic and therapeutic approaches.
  • To highlight the efficacy of various treatment modalities.

Summary:

  • Prevalence of ED is under 10% in men <50 and over 20% in men >60.
  • Risk factors include age, comorbidities like diabetes and cardiovascular disease, and psychological conditions.
  • Phosphodiesterase type 5 inhibitors (PDE5i) are effective for two-thirds of patients, with second and third-line treatments available for refractory cases.

Impact:

  • Standardized work-up and treatment protocols lead to high therapeutic success rates in managing erectile dysfunction.
  • Understanding diverse pathophysiological mechanisms guides personalized treatment strategies.
  • Effective management of ED improves patient quality of life and sexual health.